Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting
Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?
Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population. Patients often report increasing joint pain with…Abstract Number: 268 • 2013 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics…Abstract Number: 2484 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of TNFα Blockers In Patients With Psoriatic Arthritis
Background/Purpose: TNFα blockers have been shown to produce immunogenecity in patients with rheumatoid arthritis, spondyloarthrritis and inflammatory bowel diseases. Data on the induction of anti-drug…Abstract Number: 1349 • 2013 ACR/ARHP Annual Meeting
High Rate Of Improvement In Serum Matrix Metalloproteinase-3 Levels At 4 Weeks Predict Remission At 52 Weeks In RA Patients With Adalimumab Therapy
Background/Purpose : Serum MMP-3 is a specific inflammatory marker of the synovium in patients with rheumatoid arthritis (RA). Our aim in this study is to…Abstract Number: 2466 • 2013 ACR/ARHP Annual Meeting
Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Background/Purpose: Adalimumab had demonstrated good efficacy in 46 patients with active non-radiographic axial SpA in a 12-weeks, placebo-controlled trial with a 40-weeks, open-label extension.1,2In 19…Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…Abstract Number: 875 • 2013 ACR/ARHP Annual Meeting
Microrna Expression Profiles Associated With Response To Adalimumab and Methotrexate Versus Methotrexate: A Placebo-Controlled Clinical Trial
Background/Purpose: The response to anti-TNF therapy varies widely between patients with rheumatoid arthritis (RA). MicroRNAs (miRNAs) are suggested to influence susceptibility to RA and disease…Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…Abstract Number: 2366 • 2013 ACR/ARHP Annual Meeting
Economic Impact Of Adalimumab Treatment In Japanese Patients With Rheumatoid Arthritis: Analysis Of 24 Weeks Data From The Anouveau Study
Background/Purpose: Patients with rheumatoid arthritis (RA) incur higher costs owing to missed work days and short-time disability. Although methotrexate combined with adalimumab (ADA) provides comprehensive…Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting
Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor
Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…Abstract Number: 483 • 2013 ACR/ARHP Annual Meeting
Adalimumab and Methotrexate Pharmacokinetics Following Combination Therapy With Different Methotrexate Doses in Methotrexate and Biologic-Naïve Rheumatoid Arthritis Patients: Concerto Study
Background/Purpose: Higher exposure and lower immunogenicity rates have been observed for adalimumab when co-administered with methotrexate (MTX) compared to adalimumab monotherapy. The CONCERTO study was…Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- Next Page »